Subtype
Kidney and Ureter Neoplasm
CI-CAN-00001051Explore in graph →
Non-malignant518 active trials17 approved drugs81 evidence items
- NCIt
- C7514
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001051Explore in graph →
Clinical trials
2,409 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00254540 | Study of SU011248 in Patients With Advanced Kidney Cancer | completed | Phase 2 | 51 | PfizerINDUSTRY | 1 | Feb 23, 2010 | clinicaltrials |
| NCT00083889 | SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma | completed | Phase 3 | 750 | PfizerINDUSTRY | 11 | Jan 26, 2010 | clinicaltrials |
| NCT00089648 |
| SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma |
| completed |
| Phase 2 |
| 61 |
| PfizerINDUSTRY |
| 1 |
| Jan 12, 2010 |
| clinicaltrials |
| NCT00351949 | IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC) | completed | Phase 1 | 24 | Immutep S.A.S.INDUSTRY | 1 | Jan 7, 2010 | clinicaltrials |
| NCT00017329 | PS-341 in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 15, 2009 | clinicaltrials |
| NCT00625768 | Study of AS1409 in Patients With Either Metastatic Renal Cell Carcinoma or Metastatic Malignant Melanoma | completed | Phase 1 | 13 | Antisoma ResearchINDUSTRY | 2 | Aug 25, 2009 | clinicaltrials |
| NCT00077688 | TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium | completed | Phase 2 | 44 | Achieve Life SciencesINDUSTRY | 1 | Jun 4, 2009 | clinicaltrials |
| NCT00389285 | Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 52 | ZymoGeneticsINDUSTRY | 1 | May 27, 2009 | clinicaltrials |
| NCT00591188 | Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens | completed | Phase 2 | 49 | Kidney Cancer Research BureauOTHER | 1 | May 1, 2009 | clinicaltrials |
| NCT00226980 | A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma | completed | Phase 2 | 30 | Stanford UniversityOTHER | 1 | Apr 14, 2009 | clinicaltrials |
| NCT00043368 | PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) | completed | Phase 2 | 31 | PfizerINDUSTRY | 2 | Mar 12, 2009 | clinicaltrials |
| NCT00095108 | Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer | completed | Phase 1 | 43 | ZymoGeneticsINDUSTRY | 1 | Mar 9, 2009 | clinicaltrials |
| NCT00609401 | Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)(ROSORC) | completed | Phase 2 | 90 | Italian Trial in Medical OncologyOTHER | 1 | Feb 26, 2009 | clinicaltrials |
| NCT00043407 | CPG 7909 in Patients Wih Stage IV Renal Cell Cancer | completed | Phase 1 / Phase 2 | 42 | PfizerINDUSTRY | 0 | Feb 12, 2009 | clinicaltrials |
| NCT00005966 | Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer | completed | Phase 3 | — | Eastern Cooperative Oncology GroupNETWORK | 4 | Feb 5, 2009 | clinicaltrials |
| NCT00216801 | Relationship of Ochratoxin A to Upper Urologic Cancers | completed | — | 60 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Jan 21, 2009 | clinicaltrials |
| NCT00496301 | Clinical Trial on the Mixture of G, C and S in Treatment of Patients With RCC(SOGUG-02-06) | completed | Phase 2 | 40 | Spanish Oncology Genito-Urinary GroupOTHER | 1 | Jan 14, 2009 | clinicaltrials |
| NCT00421512 | A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients | completed | Phase 1 | 28 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 11, 2008 | clinicaltrials |
| NCT00425204 | Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment | completed | Phase 2 | 31 | AmgenINDUSTRY | 0 | Sep 15, 2008 | clinicaltrials |
| NCT00422786 | Phase II Study of CAP-232 in Patients With Refractory Metastatic Renal Cell Carcinoma | completed | Phase 2 | 10 | Thallion PharmaceuticalsINDUSTRY | 1 | Jul 15, 2008 | clinicaltrials |
| NCT00095186 | Safety/Efficacy Study of Oral Recombinant Human Lactoferrin in Renal Cell Carcinoma | completed | Phase 2 | 40 | AgennixINDUSTRY | 1 | Apr 10, 2008 | clinicaltrials |
| NCT00059735 | A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma | completed | Phase 2 | 30 | Eisai Inc.INDUSTRY | 2 | Mar 5, 2008 | clinicaltrials |
| NCT00001302 | A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833 | completed | Phase 1 | 80 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001383 | A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 | completed | Phase 1 | 52 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001570 | A Phase I Study of Continuous Intravenous Infusion of PSC 833 and Vinblastine in Patients With Metastatic Renal Cancer | completed | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001668 | Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors | completed | — | 75 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001683 | A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer | completed | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00056173 | Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Aptose Biosciences Inc.INDUSTRY | 1 | Jan 7, 2008 | clinicaltrials |
| NCT00073112 | A Study of ABT-751 in Patients With Renal Cell Cancer | completed | Phase 2 | 60 | AbbottINDUSTRY | 2 | Nov 29, 2007 | clinicaltrials |
| NCT00073125 | Safety and Efficacy of ABT-510 in Subjects With Advanced Renal Cell Carcinoma | completed | Phase 2 | 103 | AbbottINDUSTRY | 2 | Aug 15, 2007 | clinicaltrials |
| NCT00054886 | Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer | completed | Phase 2 | 63 | PfizerINDUSTRY | 1 | May 7, 2007 | clinicaltrials |
| NCT00134186 | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer | completed | Phase 2 | 43 | Pharmacyclics LLC.INDUSTRY | 1 | Mar 5, 2007 | clinicaltrials |
| NCT00263107 | Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction. | completed | — | 270 | University of California, DavisOTHER | 1 | May 31, 2006 | clinicaltrials |
| NCT00291369 | Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis | completed | Phase 3 | 456 | Centre Leon BerardOTHER | 1 | Feb 16, 2006 | clinicaltrials |
Data updated 22 days agoSource updated Feb 23, 2010source: clinicaltrials